CytomX appoints Charles Fuchs to Board of Directors as Class II director

CytomX Therapeutics, Inc.

Dr. Fuchs appointed effective July 24, 2026, as Class II director with term expiring at 2029 annual meeting.
Receives option to purchase 118,000 shares at closing price on appointment date, vesting monthly over 3 years.
Will receive standard non-employee director compensation and enter into indemnification agreement.
No material transactions or arrangements between Dr. Fuchs and the Company exceeding $120,000.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Charles Fuchs

Director

CTMX · CytomX Therapeutics, Inc.

Effective: 2026-07-24
Filed: July 27, 2026, 8:05 AM ET

On July 24, 2026, Charles Fuchs, M.D., M.P.H., was appointed to the Board of Directors (the “Board”) of CytomX Therapeutics, Inc. (the “Company”), effective immediately, as a Class II director

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Charles Fuchs was appointed as Director at CytomX Therapeutics, Inc..

Action: appointed
Role: Director

Exact text from the filing

On July 24, 2026, Charles Fuchs, M.D., M.P.H., was appointed to the Board of Directors (the “Board”) of CytomX Therapeutics, Inc. (the “Company”), effective immediately, as a Class II director

View on SEC.gov

CytomX Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-316929

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.